​

Prime Medicine (PRME) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

PRME Stock Forecast

Prime Medicine (PRME) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $17.25, with a high of $23.00 and a low of $12.00. This represents a 1291.13% increase from the last price of $1.24.

- $5 $10 $15 $20 $25 High: $23 Avg: $17.25 Low: $12 Last Closed Price: $1.24

PRME Stock Rating

Prime Medicine stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

PRME Price Target Upside V Benchmarks

TypeNameUpside
StockPrime Medicine1291.13%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$15.00
Last Closing Price$1.24$1.24$1.24
Upside/Downside--1109.68%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25471--12
Mar, 25471--12
Feb, 25471--12
Jan, 25472--13
Dec, 24472--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 07, 2024Maury RaycroftJefferies$15.00$5.40177.78%1109.68%
Apr 02, 2024David NierengartenWedbush$12.00$6.3289.87%867.74%
Oct 09, 2023Kostas BiliourisBMO Capital$19.00$8.75117.14%1432.26%
Nov 14, 2022Morgan Stanley$23.00$21.128.90%1754.84%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 01, 2024BMO CapitalOutperformOutperformhold
May 20, 2024H.C. WainwrightBuyinitialise
May 15, 2024CitigroupBuyupgrade
Apr 08, 2024Cowen & Co.Buyinitialise
Apr 03, 2024WedbushBuyOutperforminitialise
Apr 02, 2024WedbushBuyinitialise
Nov 14, 2022Morgan StanleyEqual-Weightinitialise

Financial Forecast

EPS Forecast

$-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.25$-2.18$-1.65----
Avg Forecast$-4.18$-1.90$-1.60$-1.22$-1.11$-1.34$-1.31
High Forecast$0.73$-1.69$-1.32$-0.86$-0.02$-0.57$0.23
Low Forecast$-7.45$-2.01$-1.82$-1.61$-1.72$-1.80$-2.33
Surprise %-70.10%14.74%3.13%----

Revenue Forecast

$0 $13M $26M $39M $52M $65M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported--$2.98M----
Avg Forecast$4.00M$4.44M$11.55M$18.03M$39.16M$6.52M$16.24M
High Forecast$6.41M$7.12M$27.13M$28.87M$62.72M$6.74M$26.01M
Low Forecast$385.42K$428.24K$5.16M$1.74M$3.77M$6.30M$1.56M
Surprise %---74.17%----

Net Income Forecast

$-700M $-540M $-380M $-220M $-60M $100M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-121.82M$-198.13M$-195.88M----
Avg Forecast$-380.25M$-168.36M$-142.97M$-112.21M$-78.92M$-107.79M$-118.93M
High Forecast$66.44M$-153.57M$-120.44M$-77.81M$-1.67M$-52.26M$20.78M
Low Forecast$-677.62M$-183.14M$-165.50M$-146.60M$-156.18M$-163.32M$-211.94M
Surprise %-67.96%17.69%37.01%----

PRME Forecast FAQ

Is Prime Medicine stock a buy?

Prime Medicine stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Prime Medicine is a favorable investment for most analysts.

What is Prime Medicine's price target?

Prime Medicine's price target, set by 7 Wall Street analysts, averages $17.25 over the next 12 months. The price target range spans from $12 at the low end to $23 at the high end, suggesting a potential 1291.13% change from the previous closing price of $1.24.

How does Prime Medicine stock forecast compare to its benchmarks?

Prime Medicine's stock forecast shows a 1291.13% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Prime Medicine over the past three months?

  • April 2025: 33.33% Strong Buy, 58.33% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 58.33% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 58.33% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is Prime Medicine’s EPS forecast?

Prime Medicine's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.22, marking a -26.06% decrease from the reported $-1.65 in 2024. Estimates for the following years are $-1.11 in 2026, $-1.34 in 2027, and $-1.31 in 2028.

What is Prime Medicine’s revenue forecast?

Prime Medicine's average annual revenue forecast for its fiscal year ending in December 2025 is $18.03M, reflecting a 504.33% increase from the reported $2.98M in 2024. The forecast for 2026 is $39.16M, followed by $6.52M for 2027, and $16.24M for 2028.

What is Prime Medicine’s net income forecast?

Prime Medicine's net income forecast for the fiscal year ending in December 2025 stands at $-112M, representing a -42.72% decrease from the reported $-196M in 2024. Projections indicate $-78.925M in 2026, $-108M in 2027, and $-119M in 2028.